DGIdb - SLC6A4 Gene Record

SLC6A4 6532 Druggable Genome

Alternate Names:

6532
SOLUTE CARRIER FAMILY 6 MEMBER 4
SLC6A4
5-HTT
5-HTTLPR
5HTT
HTT
OCD1
SERT
SERT1
hSERT
182138
11050
ENSG00000108576
OTTHUMG00000132751
P31645
SODIUM-DEPENDENT SEROTONIN TRANSPORTER (5HT TRANSPORTER) (5HTT). [SOURCE:UNIPROT/SWISSPROT;ACC:P31645]
SC6A4_HUMAN
SODIUM-DEPENDENT SEROTONIN TRANSPORTER
PA312
5HT transporter

Gene Info:

Human Readable Name	DRUGGABLE GENOME
Uniprot Evidence	1: Evidence at protein level
Interpro Type	Family
Interpro Short Name	Na/ntran_symport
Interpro Name	Sodium:neurotransmitter symporter
Uniprot Status	Swiss-Prot
Interpro Acc	IPR000175
Human Readable Name	TRANSPORTER
Target Class	Transporters
Target Subclass	TC:2.A.22.1.1
Target Class	Transporter
Target Subclass	Other
Transmembrane Helix Count	12
Target Subclass	SLC
Target Subclass	SLC6
Target Main Class	Transporters
Gene Biotype	PROTEIN_CODING

(6 More Sources)

Gene Categories: Category Details

TRANSPORTER
DRUGGABLE GENOME

Publications:

Hunziker et al., 2005, Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder., Clin Ther
Karpa et al., 2002, Duloxetine pharmacology: profile of a dual monoamine modulator., CNS Drug Rev
Gould et al., 2007, Effect of chronic administration of duloxetine on serotonin and norepinephrine transporter binding sites in rat brain., Biol. Psychiatry
Trivedi et al., 2008, Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine., Int Clin Psychopharmacol
Chen et al., 2005, The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors., Eur Neuropsychopharmacol
Troelsen et al., 2005, Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter., Psychopharmacology (Berl.)
van Groeningen et al., 1989, Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer., Eur J Cancer Clin Oncol
Vaishnavi et al., 2004, Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity., Biol. Psychiatry
Jost et al., 2004, Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus., Clin. Auton. Res.
Mirza et al., 2007, Serotonin transporter density and anxiolytic-like effects of antidepressants in mice., Prog. Neuropsychopharmacol. Biol. Psychiatry
Bymaster et al., 2005, The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression., Curr. Pharm. Des.
Khullar et al., 2010, Mixed incontinence: current evidence and future perspectives., Neurourol. Urodyn.
Carter et al., 2009, Duloxetine: a review of its use in the treatment of generalized anxiety disorder., CNS Drugs
Béïque et al., 1998, Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters., Eur. J. Pharmacol.
Stahl, 2008, Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines., CNS Spectr
Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
Crist RC et al., 2018, Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate., Am J Drug Alcohol Abuse
Hu Y et al., 2012, Berberine and evodiamine influence serotonin transporter (5-HTT) expression via the 5-HTT-linked polymorphic region., Pharmacogenomics J
Patkar et al., 2002, Serotonin transporter polymorphisms and measures of impulsivity, aggression, and sensation seeking among African-American cocaine-dependent individuals., Psychiatry Res
Barker et al., 1999, Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter., J. Neurosci.
Carrera et al., 2004, Cocaine pharmacology and current pharmacotherapies for its abuse., Bioorg. Med. Chem.
Corey et al., 1994, A cocaine-sensitive Drosophila serotonin transporter: cloning, expression, and electrophysiological characterization., Proc. Natl. Acad. Sci. U.S.A.
Reddy et al., 2010, Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician., Curr Med Res Opin
Liebowitz et al., 2010, Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials., Prim Care Companion J Clin Psychiatry
Perry et al., 2009, Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder., Clin Ther
Mason et al., 2007, Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter., J. Pharmacol. Exp. Ther.
Deecher et al., 2006, Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor., J. Pharmacol. Exp. Ther.
Kamath et al., 2008, Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence., Expert Rev Neurother
Calabrò M et al., 2020, Psychiatric disorders and SLC6A4 gene variants: possible effects on alcohol dependence and alzheimer's disease., Mol Biol Rep
Ushijima et al., 2005, Chronopharmacological study of antidepressants in forced swimming test of mice., J. Pharmacol. Exp. Ther.
Werling et al., 2007, A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder., Exp. Neurol.
Kalia, 2005, Neurobiological basis of depression: an update., Metab. Clin. Exp.
Gould et al., 2006, A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters., Biol. Psychiatry
Bryson HM et al., 1996, Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states., Drugs Aging
Van Ameringen et al., 2009, Pharmacotherapy for social anxiety disorder: an update., Isr J Psychiatry Relat Sci
Shang et al., 2007, Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study., J Clin Psychopharmacol
Malizia et al., 1997, Demonstration of clomipramine and venlafaxine occupation at serotonin reuptake sites in man in vivo., J. Psychopharmacol. (Oxford)
Westenberg, 2009, Recent advances in understanding and treating social anxiety disorder., CNS Spectr
Béïque et al., 2000, Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat., Neuropharmacology
Sindrup et al., 2005, Antidepressants in the treatment of neuropathic pain., Basic Clin. Pharmacol. Toxicol.
Bymaster et al., 2001, Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors., Neuropsychopharmacology
Spurlock et al., Lack of effect of antidepressant drugs on the levels of mRNAs encoding serotonergic receptors, synthetic enzymes and 5HT transporter., Neuropharmacology
Diamond et al., 2006, Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade., Eur Neuropsychopharmacol
Whale R et al., 2000, Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine., Psychopharmacology (Berl)
Gillman, 2007, Tricyclic antidepressant pharmacology and therapeutic drug interactions updated., Br. J. Pharmacol.
Borkowska et al., [The effect of sertraline on cognitive functions in patients with obsessive-compulsive disorder]., Psychiatr. Pol.
Suhara et al., 2003, High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography., Arch. Gen. Psychiatry
Alvarez et al., 1999, Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine., Clin. Pharmacol. Ther.
Larsen et al., 2004, Selectivity of (3)H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects., Br. J. Pharmacol.
Heusser et al., 2006, Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects., Clin. Pharmacol. Ther.
Gomis Barbará, [Pharmacological treatment of obesity]., Rev Med Univ Navarra
Birkenfeld et al., 2005, Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure., Clin. Auton. Res.
Jordan et al., 2005, Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials., Int J Obes (Lond)
Birkenfeld et al., 2002, Paradoxical effect of sibutramine on autonomic cardiovascular regulation., Circulation
Krahn et al., 2001, Narcolepsy and obesity: remission of severe cataplexy with sibutramine., Sleep Med.
Vazquez Roque et al., 2007, Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine., Clin. Gastroenterol. Hepatol.
Tziomalos et al., 2009, The use of sibutramine in the management of obesity and related disorders: an update., Vasc Health Risk Manag
Berke et al., 2000, Medical management of obesity., Am Fam Physician
Heusser et al., 2007, Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment., J. Clin. Endocrinol. Metab.
Sharma et al., 2008, Sibutramine: current status as an anti-obesity drug and its future perspectives., Expert Opin Pharmacother
Bang-Andersen et al., 2011, Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder., J. Med. Chem.
Wee et al., 2004, Reinforcing effect of pseudoephedrine isomers and the mechanism of action., Eur. J. Pharmacol.
Frink et al., 1996, Influence of tramadol on neurotransmitter systems of the rat brain., Arzneimittelforschung
Barann et al., 2006, Effects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: a possible mechanism for tramadol-induced early emesis., Eur. J. Pharmacol.
Driessen et al., 1992, Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro., Br. J. Pharmacol.
Barakat A, 2019, Revisiting Tramadol: A Multi-Modal Agent for Pain Management., CNS Drugs
Williams et al., 2010, Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)., Cochrane Database Syst Rev
Miolo et al., 2002, Photoisomerization of fluvoxamine generates an isomer that has reduced activity on the 5-hydroxytryptamine transporter and does not affect cell proliferation., Eur. J. Pharmacol.
Millan et al., 2003, Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes., Psychopharmacology (Berl.)
Dell'Osso et al., 2005, Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder., Expert Opin Pharmacother
Irons, 2005, Fluvoxamine in the treatment of anxiety disorders., Neuropsychiatr Dis Treat
Inoue, 2004, [Analysis and its application for prevention of side-effects of drugs and for evaluation of drug responsiveness]., Yakugaku Zasshi
McMahon et al., 2001, Role of 5-HT(2a) and 5-HT(2B/2C) receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors., Neuropsychopharmacology
Kakiuchi et al., 2001, Effects of aging on serotonin transporter availability and its response to fluvoxamine in the living brain: PET study with [(11)C](+)McN5652 and [(11)C](-)McN5652 in conscious monkeys., Synapse
Yoshida et al., 2002, Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients., Prog. Neuropsychopharmacol. Biol. Psychiatry
Rasmussen et al., 2009, A single nucleotide polymorphism in the human serotonin transporter introduces a new site for N-linked glycosylation., Neuropharmacology
Schloss et al., 1995, Heterogeneity of antidepressant binding sites on the recombinant rat serotonin transporter SERT1., Biochemistry
Plenge et al., 2005, High- and low-affinity binding of S-citalopram to the human serotonin transporter mutated at 20 putatively important amino acid positions., Neurosci. Lett.
Dugar et al., 2001, Compensatory responses in the aging hippocampal serotonergic system following neurodegenerative injury with 5,7-dihydroxytryptamine., Synapse
Bareggi et al., 2007, The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders., Expert Opin Drug Metab Toxicol
Vicentic et al., 1999, Serotonin transporter production and degradation rates: studies with RTI-76., Brain Res.
Eriksson et al., 1999, Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain., Neuropsychopharmacology
Dutta et al., 2001, Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters., J. Med. Chem.
Zhong et al., 2009, An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant., Neurosci. Lett.
Maines et al., 1999, Corticosterone regulation of serotonin transporter and 5-HT1A receptor expression in the aging brain., Synapse
Coleman JA et al., 2016, X-ray structures and mechanism of the human serotonin transporter., Nature
Sangkuhl K et al., 2011, PharmGKB summary: citalopram pharmacokinetics pathway., Pharmacogenet Genomics
Zhu XL et al., 2020, Correlations of analgesic dosage of morphine with SLC6A4 gene polymorphisms in patients with lung cancer., Eur Rev Med Pharmacol Sci
Frazer et al., 1998, Serotonin transporter function in vivo: assessment by chronoamperometry., Ann. N. Y. Acad. Sci.
Kovachich et al., 1992, Effect of repeated administration of antidepressants on serotonin uptake sites in limbic and neocortical structures of rat brain determined by quantitative autoradiography., Neuropsychopharmacology
McDougle et al., 1998, Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder., Mol. Psychiatry
Daws et al., 1998, In vivo chronoamperometric measures of extracellular serotonin clearance in rat dorsal hippocampus: contribution of serotonin and norepinephrine transporters., J. Pharmacol. Exp. Ther.
Rouillon et al., 1996, [Pharmaco-epidemiologic study of the use of antidepressant drugs in the general population]., Encephale
Numachi et al., 2007, Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters., Eur. J. Pharmacol.
Sora et al., 2009, Monoamine transporter as a target molecule for psychostimulants., Int. Rev. Neurobiol.
Tellez et al., 2010, Autoradiographic study of serotonin transporter during memory formation., Behav. Brain Res.
Benmansour et al., 2002, Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter., J. Neurosci.
Benmansour et al., 1999, Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level., J. Neurosci.
Iehlé et al., 1993, Baculovirus-directed expression of human prostatic steroid 5 alpha-reductase 1 in an active form., J. Steroid Biochem. Mol. Biol.
Chen et al., 2005, Characterization of an allosteric citalopram-binding site at the serotonin transporter., J. Neurochem.
Durham et al., 2004, The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder., Psychopharmacology (Berl.)
David et al., 2001, Comparison of antidepressant activity in 4- and 40-week-old male mice in the forced swimming test: involvement of 5-HT1A and 5-HT1B receptors in old mice., Psychopharmacology (Berl.)
Muneoka et al., 2009, Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats., Neurochem. Res.
Rogóz et al., Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats., Pharmacol Rep
Johnson BA et al., 2011, Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking., Am J Psychiatry
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Schloss P et al., 1998, The serotonin transporter: a primary target for antidepressant drugs., J Psychopharmacol
Rausch et al., 2003, Initial platelet serotonin (5-HT) transport kinetics predict nortriptyline treatment outcome., J Clin Psychopharmacol
Joyce et al., 2003, Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline., Int. J. Neuropsychopharmacol.
Wisner et al., 2006, Postpartum depression: a randomized trial of sertraline versus nortriptyline., J Clin Psychopharmacol
Pollock et al., 2000, Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression., Neuropsychopharmacology
Gören et al., 2007, Fluoxetine partly exerts its actions through GABA: a neurochemical evidence., Neurochem. Res.
Sanders et al., 2007, Chronic blockade or constitutive deletion of the serotonin transporter reduces operant responding for food reward., Neuropsychopharmacology
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Richman et al., 2007, Seizure prophylaxis in an animal model of epilepsy by dietary fluoxetine supplementation., Epilepsy Res.
Iceta et al., 2007, Effect of long-term fluoxetine treatment on the human serotonin transporter in Caco-2 cells., Life Sci.
Ranganathan et al., 2001, Mutations in the Caenorhabditis elegans serotonin reuptake transporter MOD-5 reveal serotonin-dependent and -independent activities of fluoxetine., J. Neurosci.
Davis et al., 1997, Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression., Drugs
Taylor et al., 1995, Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug., J Clin Psychiatry
Narayan et al., 1998, Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin., J Clin Psychopharmacol
Owens et al., 1995, The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies., Life Sci.
Leboyer et al., 1999, Decreased serotonin transporter binding in unaffected relatives of manic depressive patients., Biol. Psychiatry
Barkan et al., 2004, Biochemical and pharmacological characterization of the serotonin transporter in human peripheral blood lymphocytes., Eur Neuropsychopharmacol
Scholze et al., 2000, Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter., J. Pharmacol. Exp. Ther.
Quintin et al., 2001, Clinical and neurochemical effect of acute tryptophan depletion in unaffected relatives of patients with bipolar affective disorder., Biol. Psychiatry
Goulet et al., 2001, Non-amines, drugs without an amine nitrogen, potently block serotonin transport: novel antidepressant candidates?, Synapse
Russell et al., 2001, The effect of (R)-HA966 or ACEA 1021 on dexfenfluramine or (S)-MDMA-induced changes in temperature, activity, and neurotoxicity., Pharmacol. Biochem. Behav.
Eddahibi et al., 2001, Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats., J. Pharmacol. Exp. Ther.
Wang et al., 2004, 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein., Synapse
Rothman et al., 2003, High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain., Synapse
Johnson et al., 2003, The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux., J. Thromb. Haemost.
Rothman et al., 1999, Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension., Circulation
Mekontso-Dessap et al., 2006, Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice., Circulation
Zolkowska et al., 2006, Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease., J. Pharmacol. Exp. Ther.
John et al., 2007, Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices., Neuropharmacology
Leo et al., 2006, Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain., Curr Opin Investig Drugs
Moret et al., 1985, Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug., Neuropharmacology
Stahl SM, 2009, Mechanism of action of trazodone: a multifunctional drug., CNS Spectr
Dresel et al., 1999, In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates., Eur J Nucl Med
Stehouwer et al., 2006, Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography., J. Med. Chem.
Izenwasser et al., 1999, Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine., Eur. J. Pharmacol.
López-Rodríguez R et al., 2013, Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers., Pharmacogenomics
Vázquez-Bourgon J et al., 2010, Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis., Psychiatry Res
Hoffman et al., 1998, In vivo electrochemical studies of dopamine clearance in the rat substantia nigra: effects of locally applied uptake inhibitors and unilateral 6-hydroxydopamine lesions., J. Neurochem.
Holmes et al., 2002, Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter., Neuropsychopharmacology
Zhou et al., 2006, Evidence that serotonin reuptake modulators increase the density of serotonin innervation in the forebrain., J. Neurochem.
Larsen MH et al., 2007, Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine., Eur J Pharmacol
Vanover KE et al., 2019, Dopamine D<sub>2</sub> receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia., Neuropsychopharmacology
Cloonan SM et al., 2009, Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents., Eur J Med Chem
Porcelli S et al., 2016, Possible biomarkers modulating haloperidol efficacy and/or tolerability., Pharmacogenomics
Quaak M et al., 2012, Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation., Addiction
Preuss et al., 2000, Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity., Psychiatry Res
Wihlbäck et al., 2001, Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin 2A receptor binding., Obstet Gynecol
Haughey et al., 2000, The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia., J. Neurochem.
Davis BA et al., 2016, Mechanism of Paroxetine (Paxil) Inhibition of the Serotonin Transporter., Sci Rep
Foster RH et al., 1997, Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder., CNS Drugs
Kohlrausch FB et al., 2010, Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics., J Psychiatr Res
Fabre et al., [Mechanisms of action of antidepressants: new data from Escitalopram]., Encephale
Owens et al., 2001, Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine., Biol. Psychiatry
Waugh et al., 2003, Escitalopram : a review of its use in the management of major depressive and anxiety disorders., CNS Drugs
Sánchez et al., 2003, Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities., Psychopharmacology (Berl.)
Burke, 2002, Escitalopram., Expert Opin Investig Drugs
Owens et al., [Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine]., Encephale
Sanchez C et al., 2014, A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?, Int Clin Psychopharmacol

DEXFENFLURAMINE SLC6A4

Interaction Score: 8.32

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
11325413 11259539 15266556 14515341 14675103

Sources:
TdgClinicalTrial TEND
SIBUTRAMINE SLC6A4

Interaction Score: 3.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name sibutramine HCl monohydrate,Meridia, Reductil, Reduxade, Zelium

Novel drug target Established target

PMIDs:
16678551 15382615 15944869 15685250 12417543 11152984 17544870 19475780 10929704 17284621 18671470

Sources:
TdgClinicalTrial TEND
4-METHYLTHIOAMPHETAMINE SLC6A4

Interaction Score: 2.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19717215

Sources:
DTC
PHENTERMINE SLC6A4

Interaction Score: 2.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
10458725 16380550 16644904 14675103 17459426

Sources:
TdgClinicalTrial TEND
DESVENLAFAXINE SLC6A4

Interaction Score: 1.9

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Pristiq

Novel drug target Established target

PMIDs:
19919295 20944767 19698900 17673606 16675639 19086875

Sources:
TdgClinicalTrial TEND
PROTRIPTYLINE SLC6A4

Interaction Score: 1.36

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
9928259 1476595 9672904 9537821 9694957 8767026

Sources:
TdgClinicalTrial TEND
EVODIAMINE SLC6A4

Interaction Score: 1.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21647174

Sources:
PharmGKB
FLUVOXAMINE SLC6A4

Interaction Score: 1.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name fluvoxamine , fluvoxamine-CR,Luvox

Novel drug target Established target

PMIDs:
20687077 12208313 12721776 12695316 16316311 18568110 15170064 11166521 11304754 11817517

Sources:
TdgClinicalTrial TEND
DULOXETINE SLC6A4

Interaction Score: 1.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Cymbalta

Novel drug target Established target

PMIDs:
16199241 12481192 16650830 18408530 15695064 16032412 2784100 14744476 15316838 17335951 15892657 20432324 19480470 9669506

Sources:
TdgClinicalTrial TEND
CLOMIPRAMINE SLC6A4

Interaction Score: 1.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
10867985 17471183 12647451 9537821 12695316 9305421 10613618 14993096

Sources:
TdgClinicalTrial TEND PharmGKB
MINAPRINE SLC6A4

Interaction Score: 0.99

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
17016423 17139284 9694022

Sources:
TdgClinicalTrial TEND
IMIPRAMINE SLC6A4

Interaction Score: 0.97

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
10624553 7548008 9537821 15056483 10869387 11513817 11746710

Sources:
TdgClinicalTrial TEND
MILNACIPRAN SLC6A4

Interaction Score: 0.95

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Milnacipran

Novel drug target Established target

PMIDs:
16869117 3005901

Sources:
TdgClinicalTrial TEND
VENLAFAXINE SLC6A4

Interaction Score: 0.95

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Effexor

Novel drug target Established target

PMIDs:
19728573 15695064 17224717 9537821 9305421 19238127 16140280 10884561 15910402 11750180

Sources:
TdgClinicalTrial TEND
AMITRIPTYLINE SLC6A4

Interaction Score: 0.91

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name amitriptyline + ketamine,Epicept NP-1

Novel drug target Established target

Trial Name OMS-103HP

PMIDs:
16079297 17689532 14744476 15877309 9537821 16032412 16140280 8736630

Sources:
TdgClinicalTrial TEND
NORTRIPTYLINE SLC6A4

Interaction Score: 0.86

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CRx-191

Novel drug target Established target

Trial Name CRx-170

PMIDs:
12640215 9537821 14744476 14604448 16855451 11027924

Sources:
TdgClinicalTrial TEND
NEFAZODONE SLC6A4

Interaction Score: 0.83

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
9098663 9537821 7649970 9472845 7475971

Sources:
TdgClinicalTrial TEND
TESOFENSINE SLC6A4

Interaction Score: 0.79

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name tesofensine, NS-2330

Novel drug target Established target

PMIDs:
17112503

Sources:
TdgClinicalTrial
ESCITALOPRAM SLC6A4

Interaction Score: 0.73

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Cipralex, escitalopram,Lexapro

Novel drug target Established target

PMIDs:
12876551 17916059 19616061 11543737 12665392 12719960 12387707 12232544 24424469

Sources:
TdgClinicalTrial TEND
SERTRALINE SLC6A4

Interaction Score: 0.68

Interaction Types & Directionality:

negative modulator (inhibitory)

binder

inhibitor (inhibitory)

Interaction Info:

Trial Name Zoloft

Novel drug target Established target

PMIDs:
12151556 10575045 8664165 9537821 15606893 12647451 12955294 11243491 18751896 16963794

Sources:
TdgClinicalTrial TEND
TRIMIPRAMINE SLC6A4

Interaction Score: 0.68

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
9537821 16388933

Sources:
TdgClinicalTrial TEND
SOLRIAMFETOL SLC6A4

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name YKP-10A

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
DAPOXETINE SLC6A4

Interaction Score: 0.59

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name dapoxetine,Priligy

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
LEVOMILNACIPRAN SLC6A4

Interaction Score: 0.59

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name levomilnacipran, F2695

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
BERBERINE SLC6A4

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21647174

Sources:
PharmGKB
DESIPRAMINE SLC6A4

Interaction Score: 0.55

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
9422361 12464448 16140280 9537821 16300628

Sources:
TdgClinicalTrial TEND
CITALOPRAM SLC6A4

Interaction Score: 0.54

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
19500602 7548008 15955412 11180498 17916059 9537821 10546982 10063489 11300876 19616061 10188639 27049939 21546862

Sources:
TdgClinicalTrial TEND
PAROXETINE SLC6A4

Interaction Score: 0.5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CRx-139

Novel drug target Established target

Trial Name paroxetine hydrochloride,Paxil, Seroxat

PMIDs:
10980326 9537821 10869387 11530128 11027924 10987842 27032980 23338224

Sources:
TdgClinicalTrial TEND
FLUOXETINE SLC6A4

Interaction Score: 0.48

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

Trial Name NPL-2008, Fluoxetine

Trial Name fluoxetine HCl,Prozac

PMIDs:
17486443 17356573 9537821 11752352 17335951 17215106 17289086 11487610

Sources:
TdgClinicalTrial NCI TEND
LUMATEPERONE SLC6A4

Interaction Score: 0.48

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name ITI-007, ITI-722

Novel drug target Established target

PMIDs:
30449883

Sources:
TdgClinicalTrial
TRAMADOL SLC6A4

Interaction Score: 0.4

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name PTI-601

Novel drug target Established target

Trial Name tramadol extended-release,Raliva ER

PMIDs:
8955860 16427041 1596676 31004280

Sources:
TdgClinicalTrial TEND
VORTIOXETINE SLC6A4

Interaction Score: 0.4

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Lu AA21004

PMIDs:
21486038

Sources:
TdgClinicalTrial
COCAINE SLC6A4

Interaction Score: 0.4

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12057823 9537821 10366604 15351386 8302852

Sources:
TdgClinicalTrial TEND
TRAZODONE SLC6A4

Interaction Score: 0.37

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name trazodone extended release, DDS-04A,Oleptro

Novel drug target Established target

PMIDs:
9537821 20095366

Sources:
TdgClinicalTrial TEND
AMOXAPINE SLC6A4

Interaction Score: 0.34

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CRx-150, amoxapine plus dipyridamole

Novel drug target Established target

Trial Name CRx-119

PMIDs:
7984281 9537821

Sources:
TdgClinicalTrial TEND
ONDANSETRON SLC6A4

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21247998

Sources:
PharmGKB
DOXEPIN SLC6A4

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name doxepin nasal solution,Dolorac

Novel drug target Established target

Trial Name Silenor (SO-101)

PMIDs:
19179941 9537821

Sources:
TdgClinicalTrial TEND
BUPRENORPHINE SLC6A4

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29333880

Sources:
PharmGKB
METHAMPHETAMINE SLC6A4

Interaction Score: 0.18

Interaction Types & Directionality:

negative modulator (inhibitory)

Interaction Info:

Trial Name low dose intravenous methamphetamine

Novel drug target Established target

PMIDs:
17673199 19607959 20226815

Sources:
TdgClinicalTrial
BUPROPION SLC6A4

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21658141

Sources:
PharmGKB
PSEUDOEPHEDRINE SLC6A4

Interaction Score: 0.14

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name fexofenadine + ps/

Novel drug target Established target

PMIDs:
15189772

Sources:
TdgClinicalTrial
QUETIAPINE SLC6A4

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23859574 20031235

Sources:
PharmGKB
METHYLPHENIDATE SLC6A4

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name methylphenidate HCl,Concerta

Novel drug target Established target

Trial Name methylphenidate HCl,Metadate CD, Equasym

PMIDs:
10199939 17154506 10414438

Sources:
TdgClinicalTrial TEND
TEDATIOXETINE SLC6A4

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name Lu AA24530

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
METHADONE SLC6A4

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29333880

Sources:
PharmGKB
MORPHINE SLC6A4

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
32432768

Sources:
PharmGKB
RISPERIDONE SLC6A4

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23859574 20031235

Sources:
PharmGKB
HALOPERIDOL SLC6A4

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437 20031235

Sources:
PharmGKB
OLANZAPINE SLC6A4

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23859574 20031235

Sources:
PharmGKB
CLOZAPINE SLC6A4

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20452607

Sources:
PharmGKB
RIBAVIRIN SLC6A4

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ALCOHOL SLC6A4

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31595439

Sources:
PharmGKB

Ensembl: ENSG00000108576
- Version: 101_38
Alternate Names:

SLC6A4 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
RussLampel: ENSG00000108576
- Version: 26-July-2011
Alternate Names:

SODIUM-DEPENDENT SEROTONIN TRANSPORTER (5HT TRANSPORTER) (5HTT). [SOURCE:UNIPROT/SWISSPROT;ACC:P31645] Description

SLC6A4 Display Id

ENSG00000108576 Ensembl Gene Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:
HopkinsGroom: P31645
- Version: 11-September-2012
Alternate Names:

6532 Entrez Gene Id

P31645 Uniprot Accession

SODIUM-DEPENDENT SEROTONIN TRANSPORTER Uniprot Protein Name

Gene Info:

Uniprot Evidence 1: Evidence at protein level

Interpro Type Family

Interpro Short Name Na/ntran_symport

Gene Categories:

TRANSPORTER, DRUGGABLE GENOME

Publications:
TdgClinicalTrial: P31645
- Version: January-2014
Alternate Names:

SLC6A4 Gene Symbol

Gene Info:

Target Class Transporters

Target Subclass TC:2.A.22.1.1

Target Class Transporter

Publications:
TEND: P31645
- Version: 01-August-2011
Alternate Names:

SC6A4_HUMAN Uniprot Id

SLC6A4 Gene Symbol

P31645 Uniprot Accession

Gene Info:

Target Subclass Other

Transmembrane Helix Count 12

Target Subclass SLC

Publications:

PharmGKB: SLC6A4

Version: 18-August-2020

Alternate Names:

PA312 PharmGKB ID

Gene Info:

Publications:

Crist RC et al., 2018, Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate., Am J Drug Alcohol Abuse

Hu Y et al., 2012, Berberine and evodiamine influence serotonin transporter (5-HTT) expression via the 5-HTT-linked polymorphic region., Pharmacogenomics J

Porcelli S et al., 2016, Possible biomarkers modulating haloperidol efficacy and/or tolerability., Pharmacogenomics

NCI: SLC6A4

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Lu et al., 2003, Ovarian steroid regulation of serotonin reuptake transporter (SERT) binding, distribution, and function in female macaques., Mol. Psychiatry

Ranganathan et al., 2001, Mutations in the Caenorhabditis elegans serotonin reuptake transporter MOD-5 reveal serotonin-dependent and -independent activities of fluoxetine., J. Neurosci.

DTC: SLC6A4
- Version: 02-September-2020
Alternate Names:

Gene Info:

Publications:

Cloonan SM et al., 2009, Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents., Eur J Med Chem
HingoraniCasas: ENSG00000108576
- Version: 31-May-2017
Alternate Names:

ENSG00000108576 Gene Symbol

SLC6A4 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
Pharos: SLC6A4
- Version: 01-February-2022
Alternate Names:

Sodium-dependent serotonin transporter Gene Name

P31645 UniProt ID

Gene Info:

Gene Categories:

TRANSPORTER

Publications:

Trial Name	sibutramine HCl monohydrate,Meridia, Reductil, Reduxade, Zelium
Novel drug target	Established target

Trial Name	fluvoxamine , fluvoxamine-CR,Luvox
Novel drug target	Established target

Trial Name	amitriptyline + ketamine,Epicept NP-1
Novel drug target	Established target
Trial Name	OMS-103HP

Trial Name	CRx-191
Novel drug target	Established target
Trial Name	CRx-170

Trial Name	tesofensine, NS-2330
Novel drug target	Established target

Trial Name	Cipralex, escitalopram,Lexapro
Novel drug target	Established target

Trial Name	dapoxetine,Priligy
Novel drug target	Established target

Trial Name	levomilnacipran, F2695
Novel drug target	Established target

Trial Name	CRx-139
Novel drug target	Established target
Trial Name	paroxetine hydrochloride,Paxil, Seroxat

Trial Name	Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)
Trial Name	NPL-2008, Fluoxetine
Trial Name	fluoxetine HCl,Prozac

Trial Name	ITI-007, ITI-722
Novel drug target	Established target

Trial Name	PTI-601
Novel drug target	Established target
Trial Name	tramadol extended-release,Raliva ER

Trial Name	trazodone extended release, DDS-04A,Oleptro
Novel drug target	Established target

Trial Name	CRx-150, amoxapine plus dipyridamole
Novel drug target	Established target
Trial Name	CRx-119

Trial Name	doxepin nasal solution,Dolorac
Novel drug target	Established target
Trial Name	Silenor (SO-101)

Trial Name	low dose intravenous methamphetamine
Novel drug target	Established target

Trial Name	fexofenadine + ps/
Novel drug target	Established target

Trial Name	methylphenidate HCl,Concerta
Novel drug target	Established target
Trial Name	methylphenidate HCl,Metadate CD, Equasym

SODIUM-DEPENDENT SEROTONIN TRANSPORTER (5HT TRANSPORTER) (5HTT). [SOURCE:UNIPROT/SWISSPROT;ACC:P31645]	Description
SLC6A4	Display Id
ENSG00000108576	Ensembl Gene Id

6532	Entrez Gene Id
P31645	Uniprot Accession
SODIUM-DEPENDENT SEROTONIN TRANSPORTER	Uniprot Protein Name

SLC6A4 Gene Record

SLC6A4 6532 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 11325413 11259539 15266556 14515341 14675103

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name sibutramine HCl monohydrate,Meridia, Reductil, Reduxade, Zelium Novel drug target Established target

PMIDs: 16678551 15382615 15944869 15685250 12417543 11152984 17544870 19475780 10929704 17284621 18671470

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19717215

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 10458725 16380550 16644904 14675103 17459426

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Pristiq Novel drug target Established target

PMIDs: 19919295 20944767 19698900 17673606 16675639 19086875

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 9928259 1476595 9672904 9537821 9694957 8767026

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21647174

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name fluvoxamine , fluvoxamine-CR,Luvox Novel drug target Established target

PMIDs: 20687077 12208313 12721776 12695316 16316311 18568110 15170064 11166521 11304754 11817517

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Cymbalta Novel drug target Established target

PMIDs: 16199241 12481192 16650830 18408530 15695064 16032412 2784100 14744476 15316838 17335951 15892657 20432324 19480470 9669506

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 10867985 17471183 12647451 9537821 12695316 9305421 10613618 14993096

Sources: TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 17016423 17139284 9694022

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 10624553 7548008 9537821 15056483 10869387 11513817 11746710

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Milnacipran Novel drug target Established target

PMIDs: 16869117 3005901

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Effexor Novel drug target Established target

PMIDs: 19728573 15695064 17224717 9537821 9305421 19238127 16140280 10884561 15910402 11750180

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name amitriptyline + ketamine,Epicept NP-1 Novel drug target Established target Trial Name OMS-103HP

PMIDs: 16079297 17689532 14744476 15877309 9537821 16032412 16140280 8736630

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name CRx-191 Novel drug target Established target Trial Name CRx-170

PMIDs: 12640215 9537821 14744476 14604448 16855451 11027924

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name -

PMIDs: 9098663 9537821 7649970 9472845 7475971

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info: Trial Name tesofensine, NS-2330 Novel drug target Established target

PMIDs: 17112503

Sources: TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Cipralex, escitalopram,Lexapro Novel drug target Established target

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
11325413 11259539 15266556 14515341 14675103

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name sibutramine HCl monohydrate,Meridia, Reductil, Reduxade, Zelium

Novel drug target Established target

PMIDs:
16678551 15382615 15944869 15685250 12417543 11152984 17544870 19475780 10929704 17284621 18671470

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
19717215

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
10458725 16380550 16644904 14675103 17459426

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Pristiq

Novel drug target Established target

PMIDs:
19919295 20944767 19698900 17673606 16675639 19086875

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
9928259 1476595 9672904 9537821 9694957 8767026

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
21647174

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name fluvoxamine , fluvoxamine-CR,Luvox

Novel drug target Established target

PMIDs:
20687077 12208313 12721776 12695316 16316311 18568110 15170064 11166521 11304754 11817517

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Cymbalta

Novel drug target Established target

PMIDs:
16199241 12481192 16650830 18408530 15695064 16032412 2784100 14744476 15316838 17335951 15892657 20432324 19480470 9669506

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
10867985 17471183 12647451 9537821 12695316 9305421 10613618 14993096

Sources:
TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
17016423 17139284 9694022

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
10624553 7548008 9537821 15056483 10869387 11513817 11746710

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Milnacipran

Novel drug target Established target

PMIDs:
16869117 3005901

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Effexor

Novel drug target Established target

PMIDs:
19728573 15695064 17224717 9537821 9305421 19238127 16140280 10884561 15910402 11750180

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name amitriptyline + ketamine,Epicept NP-1

Novel drug target Established target

Trial Name OMS-103HP

PMIDs:
16079297 17689532 14744476 15877309 9537821 16032412 16140280 8736630

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CRx-191

Novel drug target Established target

Trial Name CRx-170

PMIDs:
12640215 9537821 14744476 14604448 16855451 11027924

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
9098663 9537821 7649970 9472845 7475971

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name tesofensine, NS-2330

Novel drug target Established target

PMIDs:
17112503

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Cipralex, escitalopram,Lexapro

Novel drug target Established target

PMIDs:
12876551 17916059 19616061 11543737 12665392 12719960 12387707 12232544 24424469

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

negative modulator (inhibitory)

binder

inhibitor (inhibitory)

Interaction Info:

Trial Name Zoloft

Novel drug target Established target

PMIDs:
12151556 10575045 8664165 9537821 15606893 12647451 12955294 11243491 18751896 16963794

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

SC6A4_HUMAN	Uniprot Id
SLC6A4	Gene Symbol
P31645	Uniprot Accession

Sodium-dependent serotonin transporter	Gene Name
P31645	UniProt ID